Gastric Ca
52 programs · 52 companies
Programs
52
Companies
52
Trials
43
MOAs
37
CGRPantSTINGagCDK4/6iAHRantKRASG12DiVEGFiSOS1iSGLT2iCl18.2Menini
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Phase 1/2 | CD38 | ||
| GIL-4361 | Preclinical | PCSK9 | ||
| VRT-4938 | Preclinical | HER2 | ||
| NTL-2576 | NDA/BLA | SGLT2 | ||
| DAW-5540 | Phase 2 | AHR | ||
| Tixafotisoran | Phase 3 | FLT3 | ||
| Ribonesiran | Phase 1/2 | IL-23 | ||
| 452-7432 | Phase 2 | Aβ | ||
| UCB-6099 | Approved | SHP2 | ||
| CIP-213 | Approved | Nectin-4 | ||
| NIA-IIT-554 | Phase 2/3 | IL-13 | ||
| CAM-IIT-380 | NDA/BLA | CD123 | ||
| FRE-IIT-743 | NDA/BLA | KRASG12D | ||
| MIR-7357 | Preclinical | USP1 | ||
| CHI-3786 | Phase 2 | SOS1 | ||
| INS-8557 | Phase 2/3 | TNFα | ||
| MGX-6815 | Phase 2 | Menin | ||
| SAV-8261 | NDA/BLA | IL-23 | ||
| COR-4726 | Preclinical | PRMT5 | ||
| Elratenlimab | Phase 3 | GIP-R | ||
| Sovafotisoran | Preclinical | KRASG12D | ||
| Tezerapivir | Preclinical | Menin | ||
| VND-7068 | Phase 2 | MALT1 | ||
| BLR-1526 | Preclinical | CD3 | ||
| 601-626 | Approved | GIP-R | ||
| PRI-9923 | Phase 2/3 | BCMA | ||
| 117-9336 | Phase 2/3 | PLK4 | ||
| Talatinib | Approved | WEE1 | ||
| Rilunaritide | Approved | Cl18.2 | ||
| DUK-IIT-581 | Phase 2 | APOC3 | ||
| GNL-2086 | Preclinical | CD3 | ||
| Elratapinarof | Preclinical | Nectin-4 | ||
| Tiravorutinib | Preclinical | GLP-1R | ||
| NAT-2164 | Phase 1/2 | RET | ||
| IMM-6534 | Phase 1/2 | Nectin-4 | ||
| MRK-474 | Phase 3 | PCSK9 | ||
| BER-6819 | Phase 2/3 | PRMT5 | ||
| EXA-6597 | Phase 2/3 | MDM2 | ||
| Miriratamab | Phase 2/3 | GPRC5D | ||
| Ceviglumide | Phase 1 | PLK4 | ||
| Tezetinib | Phase 1 | KIF18A | ||
| Sovasertib | Phase 2 | CD20 | ||
| Elrabrutinib | Phase 2 | USP1 | ||
| TEV-8109 | Phase 1 | CD20 | ||
| IRC-IIT-452 | Phase 1 | TNFα | ||
| PET-IIT-224 | Preclinical | WRN | ||
| FRO-9633 | Phase 3 | SGLT2 | ||
| ZEN-2386 | Phase 3 | PCSK9 | ||
| Daralemzoparlimab | Phase 1/2 | JAK2 | ||
| DER-8696 | Phase 1/2 | EGFR | ||
| Talalemzoparlimab | Phase 2/3 | IL-23 | ||
| Tixasacituzumab | Phase 1 | PRMT5 |
Trials (43)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT08559699 | Terafutibatinib | Phase 1/2 | Not yet recr... |
| NCT05254526 | VRT-4938 | Preclinical | Recruiting |
| NCT06240068 | NTL-2576 | NDA/BLA | Not yet recr... |
| NCT03663918 | DAW-5540 | Phase 2 | Recruiting |
| NCT07649708 | Ribonesiran | Phase 1/2 | Not yet recr... |
| NCT03510143 | 452-7432 | Phase 2 | Recruiting |
| NCT04618550 | UCB-6099 | Approved | Active |
| NCT06345512 | CIP-213 | Approved | Recruiting |
| NCT06386259 | CIP-213 | Approved | Completed |
| NCT04445957 | CIP-213 | Approved | Recruiting |
| NCT06843470 | CIP-213 | Approved | Recruiting |
| NCT06688558 | NIA-IIT-554 | Phase 2/3 | Not yet recr... |
| NCT03188195 | CAM-IIT-380 | NDA/BLA | Completed |
| NCT08917086 | FRE-IIT-743 | NDA/BLA | Completed |
| NCT03009547 | CHI-3786 | Phase 2 | Active |
| NCT07777522 | INS-8557 | Phase 2/3 | Not yet recr... |
| NCT08523633 | MGX-6815 | Phase 2 | Not yet recr... |
| NCT07350204 | MGX-6815 | Phase 2 | Recruiting |
| NCT04483233 | SAV-8261 | NDA/BLA | Recruiting |
| NCT03410658 | Elratenlimab | Phase 3 | Completed |